Tumor growth is associated with profound metabolic and neurochemical alterations, which can lead to the onset of anorexia−cachexia syndrome. Anorexia is defined as the loss of the desire to eat, while ...

Many important advances have occurred in the field of cancer cachexia over the past decade, including progress in understanding the mechanisms of CACS and the development of promising pharmacologic ...

A study led by scientists at the Korean Research Institute of BioScience and Biotechnology (KRIBB) in Daejeon is the first to demonstrate that Dilp8/INSL3-Lgr3/8-NUCB, neuropeptide y (NPY) signaling ...

Cancer-associated cachexia is a multifactorial wasting disorder characterized by anorexia, unintentional weight loss (WL, skeletal muscle mass with or without loss of fat mass), progressive functional ...

University of Oklahoma researcher Min Li, Ph.D., is the lead author of a new publication in Cancer Cell about cancer cachexia. Cachexia is a muscle-wasting and fat-loss condition that most often ...

Dietary Fat and Carbohydrates Are Independently Associated With Circulating Insulin-Like Growth Factor 1 and Insulin-Like Growth Factor–Binding Protein 3 Concentrations in Healthy Adults PURPOSE: ...

A majority of people with advanced cancers endure cachexia, a muscle-, fat-, and organ-wasting condition that is currently incurable and can be life-threatening. Detecting and intervening early can ...

Eating disorders are often thought of as body image disorders with symptoms of food restriction and purging. In most cases, the goal of these behaviors is to prevent weight gain. Not all eating ...

SOLANA BEACH, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (ARTL) (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to ...

The optimal therapy for anorexia and cachexia is curing the underlying cancer. [23] Unfortunately, this goal is often not attainable with currently available treatments. Thus, an integrated ...

Consistent Improvements in Weight Gain, Lean Body Mass, and Activity were Observed Across Treated Patients including +6.4% Mean Weight Gain at 12 Weeks vs −5.4% Mean Weight Loss on Placebo The Phase 2 ...